DE69427551D1 - Nalbuphinester und diese enthaltende Arzneimittel mit verzögerter Wirkstoffabgabe - Google Patents

Nalbuphinester und diese enthaltende Arzneimittel mit verzögerter Wirkstoffabgabe

Info

Publication number
DE69427551D1
DE69427551D1 DE69427551T DE69427551T DE69427551D1 DE 69427551 D1 DE69427551 D1 DE 69427551D1 DE 69427551 T DE69427551 T DE 69427551T DE 69427551 T DE69427551 T DE 69427551T DE 69427551 D1 DE69427551 D1 DE 69427551D1
Authority
DE
Germany
Prior art keywords
drug delivery
medicines containing
delayed drug
nalbuphine
esters
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69427551T
Other languages
English (en)
Other versions
DE69427551T2 (de
Inventor
Yoa-Pu Hu Oliver
Jhi-Joung Wang
Shung-Tai Ho
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Science Council
Original Assignee
National Science Council
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP5053840A external-priority patent/JPH06271578A/ja
Application filed by National Science Council filed Critical National Science Council
Application granted granted Critical
Publication of DE69427551D1 publication Critical patent/DE69427551D1/de
Publication of DE69427551T2 publication Critical patent/DE69427551T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
    • C07D489/08—Oxygen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE1994627551 1993-03-15 1994-02-21 Nalbuphinester und diese enthaltende Arzneimittel mit verzögerter Wirkstoffabgabe Expired - Lifetime DE69427551T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP5053840A JPH06271578A (ja) 1993-03-15 1993-03-15 鎮痛剤ナルブフィン前薬の誘導体
US16125793A 1993-12-02 1993-12-02

Publications (2)

Publication Number Publication Date
DE69427551D1 true DE69427551D1 (de) 2001-08-02
DE69427551T2 DE69427551T2 (de) 2002-05-16

Family

ID=26394562

Family Applications (1)

Application Number Title Priority Date Filing Date
DE1994627551 Expired - Lifetime DE69427551T2 (de) 1993-03-15 1994-02-21 Nalbuphinester und diese enthaltende Arzneimittel mit verzögerter Wirkstoffabgabe

Country Status (2)

Country Link
EP (1) EP0615756B1 (de)
DE (1) DE69427551T2 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU686203B2 (en) * 1993-07-23 1998-02-05 Toray Industries, Inc. Morphinan derivative and medicinal use
US6225321B1 (en) * 1997-06-05 2001-05-01 Oliver Yoa-Pu Hu Long analgesic acting nalbuphine polyester derivative and method of use
EP1149836B1 (de) * 2000-04-27 2003-02-26 Oliver Yoa-Pu Hu Polynalbuphinderivat
WO2007022535A2 (en) 2005-08-19 2007-02-22 Pharmacofore, Inc. Prodrugs of active agents
US8394812B2 (en) 2005-08-24 2013-03-12 Penwest Pharmaceuticals Co. Sustained release formulations of nalbuphine
ES2441766T3 (es) 2005-08-24 2014-02-06 Endo Pharmaceuticals Inc. Formulaciones de nalbufina de liberación sostenida
EP2307420B1 (de) * 2008-04-24 2011-11-30 Janssen Pharmaceutica NV Nalmefendiesterprodrugs
DK2291380T3 (da) * 2008-04-24 2011-12-05 Janssen Pharmaceutica Nv Nalmefen-prodrugs
US9918980B2 (en) 2011-04-29 2018-03-20 Rutgers, The State University Of New Jersey Method of treating dyskinesia
ES2829223T3 (es) 2011-04-29 2021-05-31 Univ Rutgers Método de tratamiento de la discinesia
US10736889B2 (en) 2011-04-29 2020-08-11 Rutgers, The State University Of New Jersey Method of treating dyskinesia
US11234974B2 (en) 2015-05-28 2022-02-01 Lumosa Therapeutics Co., Ltd. Pharmaceutical formulations for sustained release of sebacoyl dinalbuphine ester
MX2017015138A (es) * 2015-05-28 2018-03-28 Lumosa Therapeutics Co Ltd Formulaciones farmaceuticas para liberacion sostenida de ester de sebacoil dinalbufina.
EP3703694A4 (de) * 2017-11-03 2021-08-18 Nirsum Laboratories, Inc. Opioidrezeptorantagonist-prodrugs
US11186585B2 (en) 2018-08-17 2021-11-30 Kappa-Pharma LLC Compositions and methods of enhancing opioid receptor engagement by opioid hexadienoates and optionally substituted hexadienoates
CN114828961B (zh) * 2019-08-11 2024-03-29 卡帕制药有限责任公司 通过阿片类己二烯酸酯和任选取代的己二烯酸酯增强阿片受体结合的组合物及方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4464378A (en) * 1981-04-28 1984-08-07 University Of Kentucky Research Foundation Method of administering narcotic antagonists and analgesics and novel dosage forms containing same
US4668685A (en) * 1984-07-05 1987-05-26 E.I. Du Pont De Nemours And Company Substituted benzoate ester prodrug derivatives of 3-hydroxymorphinans, which are analgesics or narcotic antagonists
US4722928A (en) * 1985-12-02 1988-02-02 E. I. Du Pont De Nemours And Company N-oxide prodrug derivatives of 3-hydroxy morphinans and partial morphinans having improved oral bioavailability, pharmaceutical compositions, and processes
US4673679A (en) * 1986-05-14 1987-06-16 E. I. Du Pont De Nemours And Company Use of prodrugs of 3-hydroxymorphinans to prevent bitter taste upon buccal, nasal or sublingual administration

Also Published As

Publication number Publication date
EP0615756A1 (de) 1994-09-21
EP0615756B1 (de) 2001-06-27
DE69427551T2 (de) 2002-05-16

Similar Documents

Publication Publication Date Title
DE69427472D1 (de) Arzneimittel mit kontrollierter Wirkstoffabgabe
KR950703566A (ko) 티에노디아제핀 화합물 및 그의 의약 용도[thienodiazepine compound and medicinal use thereof]
DE69723303D1 (de) Arzneimittel mit verzögerter wirkstoffabgabe
DE69429821D1 (de) Farnesyl-derivate und diese enthaltende arzneimittel
DE69323739D1 (de) Arzneimittel infusionsvorrichtung
DE69427551D1 (de) Nalbuphinester und diese enthaltende Arzneimittel mit verzögerter Wirkstoffabgabe
AU3419593A (en) Medicine reminder and storage device
AU5441094A (en) Pharmaceutical solutions and emulsions containing taxol
AU5171293A (en) Ion-pairing of drugs for improved efficacy and delivery
DE69514192D1 (de) Arzneimittel und/oder Nahrungsmikrokapseln zur oralen Verabreichung
HUP0000474A3 (en) Arylethenesulfonamide derivatives and drug composition containing the same
FI954767A (fi) Lipofiilisiä lääkeaineita sisältävä farmaseuttinen koostumus
BR1100824A (pt) Composto e composição farmacêutica
DE69224656D1 (de) Arzneimittel
DE69328492D1 (de) Fettsäure-derivate und diese enthaltende pharmazeutische präparationen
AU4534593A (en) Compositions and methods for enhanced drug delivery
FI932655A (fi) Imidatderivat av farmaceutiskt anvaendbara antikonvulsiva sulfamat
GB9814501D0 (en) Medication dosage reminder device
DE69326539D1 (de) Zytotoxische arzneimittel therapie
DE69333072D1 (de) Topisch anzuwendendes arzneimittel enthaltend hyaluronsäure und nsaids
EP0498268A3 (en) 5-oxo-l-proline derivatives and pharmaceutical use thereof
DE69534283D1 (de) Clonidinhaltiges arzneimittel mit verzögerter wirkstoffabgabe
AU3136293A (en) Pharmaceutical tablet with pvp having an enhanced drug dissolution rate
AU3720193A (en) Hydroisoindolines and hydroisoquinolines as psychotropic drugs
IL108327A (en) Pharmaceutical composition comprising 6-chloro-5-fluoro-3-(2-thenoyl)-2-oxindole-1-carboxamide as an analgesic and anti-inflammatory agent

Legal Events

Date Code Title Description
8364 No opposition during term of opposition